Search results for "Genetic Structures"

showing 10 items of 2107 documents

Thyroid hormone deficiency disrupts rat eye neurodevelopment

2010

Clinical and experimental studies have highlighted the role played by thyroid hormones (TH) in neural and neuro-sensorial development. However, knowledge on TH mechanisms on the developing visual system is still incomplete. To uncover TH actions on the eyes and vision we carried out a microscopical study on the role of TH in the developing retina and optic nerve, in a rat model of controlled TH deficiency (THD). Morphometric and stereological analyses of the retina and optic nerve showed a reduction in the volume of the eye (p<0.001) and optic nerve cross-sectional area (p<0.001), and thinning of the retinal layers (p<0.001). Glial development and myelination was significantly delayed in th…

MaleThyroid Hormonesmedicine.medical_specialtygenetic structuresRat modelRetinachemistry.chemical_compoundHypothyroidismMicroscopy Electron TransmissionPregnancyInternal medicinemedicineAnimalsRats WistarMolecular BiologyRetinaGeneral NeuroscienceThyroidAge FactorsImidazolesOptic NerveRetinalOrgan SizeEmbryo Mammalianeye diseasesRatsDisease Models AnimalEndocrinologymedicine.anatomical_structureAnimals NewbornchemistryThyroid hormonesOptic nerveEye disorderFemalesense organsNeurology (clinical)PsychologyDevelopmental BiologyHormoneBrain Research
researchProduct

Heavy versus standard silicone oil in the management of retinal detachment with macular hole in myopic eyes

2011

PURPOSE: The purpose of this study was to compare pars plana vitrectomy (PPV) with 1000 cSt silicone oil endotamponade and PPV with densiron endotamponade for retinal detachment with macular hole and posterior staphyloma in highly myopic eyes. PATIENTS AND METHODS: In a prospective study, 30 eyes of 30 patients were randomly assigned to PPV and densiron (n = 15) or PPV with silicone oil (n = 15). All eyes had laser photocoagulation of the macular hole rim after PPV. Silicone oil or densiron was removed 12 weeks after surgery. Patients were followed-up for 6 months after oil removal. RESULTS: In the densiron group, the retinal reattachment rate was 100% with densiron in situ and 87% after it…

MaleTime FactorsVisual acuityIntraoperative Complicationgenetic structuresmedicine.medical_treatmentVisual AcuityRetinal perforationVitrectomyPostoperative ComplicationsVitrectomySilicone OilsProspective StudiesEndotamponadeIntraoperative ComplicationsMacular holeLaser Coagulationhigh myopic eyeRetinal detachmentGeneral MedicineMiddle AgedTreatment Outcomemedicine.anatomical_structureMyopia Degenerativemacular hole retinal detachmentDrainageFemalemedicine.symptomLaser coagulationDilatation PathologicHumanAdultPars planamedicine.medical_specialtyTime Factorsilicone oilOphthalmologymedicineHumansAgeddensironbusiness.industryRetinal DetachmentRetinal Perforationsmedicine.diseaseeye diseasesProspective StudieOphthalmologyRetinal PerforationPostoperative Complicationsense organsbusiness
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

''Active Collisions in Altered Gravity Reveal Eye-Hand Coordination Strategies''

2012

White, Olivier | Lefevre, Philippe | Wing, Alan M. | Bracewell, R. Martyn | Thonnard, Jean-Louis; International audience; ''Most object manipulation tasks involve a series of actions demarcated by mechanical contact events, and gaze is usually directed to the locations of these events as the task unfolds. Typically, gaze foveates the target 200 ms in advance of the contact. This strategy improves manual accuracy through visual feedback and the use of gaze-related signals to guide the hand/ object. Many studies have investigated eye-hand coordination in experimental and natural tasks; most of them highlighted a strong link between eye movements and hand or object kinematics. In this experime…

MaleTime Factorsgenetic structuresComputer sciencelcsh:MedicineAstronomical SciencesKinematicsSocial and Behavioral SciencesInertiaDIRECTION''Behavioral NeuroscienceLearning and MemoryHuman PerformancePsychologyComputer visionOBJECT MANIPULATIONlcsh:ScienceDIRECTIONmedia_commonGravity AlteredMultidisciplinaryEye–hand coordinationHand StrengthWeightlessnessMiddle AgedSpace ExplorationSensory SystemsBiomechanical PhenomenaTARGET[ SCCO.NEUR ] Cognitive science/NeuroscienceGRIP FORCE ADJUSTMENTSFemaleResearch ArticleAdult''GRIP FORCE ADJUSTMENTSMovementCognitive Neurosciencemedia_common.quotation_subjectAccelerationFixation OcularYoung AdultVISUAL INFORMATIONLOAD PERTURBATIONSHand strengthSaccadesHumansWorking MemoryBiologyHEAD MOVEMENTSARM MOVEMENTSMotor SystemsBehaviorHypergravityWeightlessnessbusiness.industryLatency Period Psychologicallcsh:REye movementSpaceflightHandCollisionGazePOINTING MOVEMENTFixation (visual)TASKlcsh:QArtificial intelligencebusinessNeuroscience
researchProduct

Odorization of a novel object can influence infant's exploratory behavior in unexpected ways.

2008

International audience; Although much is known about the development of object exploration during infancy, it remains to be understood whether and how olfaction can influence infants' interactions with novel objects. To address these issues, sixteen infants aged 7-15 months were videotaped during two consecutive 5-min free play sessions with a scented or an unscented version of visually similar objects. Results indicate that adding an odor to a novel object influenced the infants' behavior: the infants exhibited more and longer manipulations and mouthing of the unscented object than of the scented object. The differential responsiveness to the scented, relative to the unscented, object was …

MaleTime Factorsgenetic structuresmedia_common.quotation_subjectOlfaction050105 experimental psychologyDevelopmental psychologyViolaPerceptionDevelopmental and Educational PsychologyHumans0501 psychology and cognitive sciencesmedia_common[SCCO.NEUR]Cognitive science/Neuroscience05 social sciencesNovel objectInfantCognitionObject (philosophy)Play and PlaythingsSmellOdorFree playInfant BehaviorOdorants[ SCCO.NEUR ] Cognitive science/NeuroscienceExploratory BehaviorFemaleMouthingPsychologyPhotic Stimulation050104 developmental & child psychology
researchProduct

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct

Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).

2009

Purpose This prospective study examines the changes in short-term intraocular pressure (IOP) in patients with wet age-related macular degeneration (AMD) receiving intravitreal injections of 0.05 mL ranibizumab (Lucentis®) in a supine position. Methods A total of 45 eyes (45 patients, 16 M, 29 F, mean age: 78 y) received intravitreal ranibizumab injections for treatment of wet AMD (0.05 mL = 0.5 mg). The IOP was measured by Schiötz tonometry immediately preoperatively and postoperatively, and also after 3 and 10 minutes in a supine position. No history of glaucoma was present. Results The mean preoperative IOP was 22.4±5.5 mmHg in supine position. Immediately after the injection, IOP increas…

MaleVascular Endothelial Growth Factor AIntraocular pressuremedicine.medical_specialtySupine positiongenetic structuresAngiogenesis InhibitorsAntibodies Monoclonal HumanizedInjections03 medical and health sciencesTonometry Ocular0302 clinical medicineOphthalmologyRanibizumabWet age-related macular degenerationmedicineSupine PositionHumansIn patientProspective StudiesProspective cohort studyIntraocular PressureAgedAged 80 and overbusiness.industryAntibodies MonoclonalGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseeye diseasesVitreous BodyOphthalmology030221 ophthalmology & optometryWet Macular DegenerationFemalesense organsRanibizumabbusiness030217 neurology & neurosurgerymedicine.drugEuropean journal of ophthalmology
researchProduct

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

2014

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuva…

MaleVascular Endothelial Growth Factor ATriamcinolone acetonideVisual acuitygenetic structuresmedicine.medical_treatmentExtração de catarataVisual AcuityIntraocular lensCuidados intraoperatóriosAngiogenesis InhibitorsTriamcinolonelcsh:OphthalmologyLens Implantation IntraocularDiabetic retinopathyAntibodies monoclonalAged 80 and overGeneral MedicineDiabetic retinopathyMiddle AgedMulticenter studyBevacizumabTreatment OutcomeCataract extractionChemotherapy AdjuvantEstudo multicêntricoIntravitreal InjectionsFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedCataractMacular EdemaIntraoperative careOphthalmologyEdema macularmedicineAnticorpos monoclonaisHumansMacular edemaGlucocorticoidsAgedRetrospective StudiesMacular edemaDiabetic RetinopathyIntraoperative CarePhacoemulsificationbusiness.industryRetinopatia diabéticaPhacoemulsificationCataract surgeryFacoemulsificaçãomedicine.diseaseSurgeryImplante de lente intraocularOphthalmologyLens implantation intraocularlcsh:RE1-994businessFollow-Up StudiesArquivos brasileiros de oftalmologia
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct